Connect Biopharma has announced topline results from its global Phase II study evaluating rademikibart, a potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. The treatment was assessed as an add-on treatment for acute exacerbations in adult participants with chronic obstructive pulmonary disease (COPD) and type 2 inflammation. … Read More
Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases. The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed. VHB937… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
Roche and Dualitas Therapeutics have announced a research collaboration and license agreement to advance novel bispecific antibodies for immunology & inflammation (I&I) diseases. Under the terms of the agreement, Dualitas will receive $36.5 million upfront payment and may receive additional research, development and commercial milestone payments for… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
Infex Therapeutics has presented new data from its Phase IIa study of RESP-X (INFEX702), a first-in-class anti-virulence monoclonal antibody, in non-cystic fibrosis bronchiectasis (NCFB) patients colonised with Pseudomonas aeruginosa (Pa). The results were presented at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain. … Read More
Teva Pharmaceutical has announced positive topline results from an ongoing Phase IIa study of TEV ‘408, an investigational anti-interleukin-15 monoclonal antibody, in adults with coeliac disease. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care. The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have… Read More
The European Commission has granted orphan designation to asedebart (Lu AG13909) to brain health biopharmaceutical company Lundbeck’s novel investigational anti-ACTH monoclonal antibody (mAb), for the treatment of Cushing’s syndrome of endogenous origin. Cushing’s syndrome of endogenous origin includes both ACTH-dependent and ACTH-independent forms. ACTH-dependent Cushing’s syndrome is a rare, serious endocrine… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
